ATE342973T1 - Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren - Google Patents

Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren

Info

Publication number
ATE342973T1
ATE342973T1 AT98962884T AT98962884T ATE342973T1 AT E342973 T1 ATE342973 T1 AT E342973T1 AT 98962884 T AT98962884 T AT 98962884T AT 98962884 T AT98962884 T AT 98962884T AT E342973 T1 ATE342973 T1 AT E342973T1
Authority
AT
Austria
Prior art keywords
methods
low voltage
calcium channels
compositions
activated calcium
Prior art date
Application number
AT98962884T
Other languages
English (en)
Inventor
Mark Williams
Kenneth Stauderman
Michael Harpold
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/984,709 external-priority patent/US6528630B1/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE342973T1 publication Critical patent/ATE342973T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT98962884T 1997-12-03 1998-12-03 Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren ATE342973T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/984,709 US6528630B1 (en) 1997-12-03 1997-12-03 Calcium channel compositions and methods
US18893298A 1998-11-10 1998-11-10

Publications (1)

Publication Number Publication Date
ATE342973T1 true ATE342973T1 (de) 2006-11-15

Family

ID=26884607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962884T ATE342973T1 (de) 1997-12-03 1998-12-03 Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren

Country Status (8)

Country Link
EP (1) EP1042468B1 (de)
JP (1) JP2001525161A (de)
AT (1) ATE342973T1 (de)
AU (1) AU760309B2 (de)
CA (1) CA2312195A1 (de)
DE (1) DE69836229T2 (de)
ES (1) ES2274588T3 (de)
WO (1) WO1999028342A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297504B1 (en) 1997-02-28 2007-11-20 Neuromed Pharmaceuticals Ltd. Methods for identifying agonists and antagonists of human T-type calcium channels
JP2003504020A (ja) * 1999-07-02 2003-02-04 ニューロメド テクノロジーズ， インコーポレイテッド 新規な哺乳動物カルシウムチャネルならびに関連するプローブ、細胞株および方法
EP1214599A2 (de) * 1999-09-16 2002-06-19 Warner-Lambert Company Screening-verfahren für alpha2delta-1 untereinheit-bindenden liganden
US6358706B1 (en) 1999-10-26 2002-03-19 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding human alpha1G-C T-Type calcium channel
EP1280902A2 (de) * 2000-04-29 2003-02-05 Millennium Pharmaceuticals, Inc. 23949 und 32391, humane ionenkanäle und ihre verwendungen
AU2001292258A1 (en) * 2000-10-02 2002-04-15 Nippon Chemiphar Co., Ltd. Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient
UA79927C2 (en) * 2000-12-05 2007-08-10 Serono Genetics Inst Sa Polynucleotide, coding a polypeptide of potential-depending portal ionic human channel (canion), polypeptyde, antibody, method for identification of candidate modulator of canion-polypeptyde, method for treatment of bipolar disorder or schizophrenia and use of an antibody for production of drugs for treatment of schizophrenia or bipolar disorder
KR20030037081A (ko) 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
WO2003039449A2 (en) * 2001-11-07 2003-05-15 Medical Research Council Modulation of dopaminergic neurons
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
WO2004080444A2 (en) 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
WO2005000285A2 (en) 2003-06-13 2005-01-06 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
US20070178462A1 (en) * 2004-02-18 2007-08-02 Uebele Victor N Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20080003633A1 (en) * 2004-12-13 2008-01-03 Heesup Shin Methods for Relieving Neuropathic Pain by Modulating Alpha1G T-Type Calcium Channels and Mice Lacking Alpha 1G T-Type Calcium Channels
JP2010540629A (ja) 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
CA2701203A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
DK3106166T3 (da) 2008-02-29 2021-01-11 Vm Therapeutics Llc Forbindelser til behandling af smertesyndrom og andre lidelser
EP2493297B1 (de) 2009-10-30 2016-08-17 Merck Sharp & Dohme Corp. Heterocyclische amid-calciumkanalantagonisten vom typ t
EP2542155B1 (de) 2010-03-01 2015-11-04 TAU Therapeutics LLC Bildgebungsverfahren einer krankheit
EP2831071B1 (de) 2012-03-29 2018-11-14 Merck Sharp & Dohme Corp. Imidazolylmethylpiperidin-t-typ-calciumkanal-antagonisten
WO2018100206A1 (en) * 2016-12-02 2018-06-07 Sophion Bioscience A/S Seal enhancer
EP4209783A1 (de) 2016-12-02 2023-07-12 Sophion Bioscience A/S Dichtungsverstärker
CN115979923B (zh) * 2023-03-20 2023-06-27 中国有色金属工业昆明勘察设计研究院有限公司 一种尾矿库渗透破坏模拟试验装置及试验方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2147184T3 (es) * 1991-08-15 2000-09-01 Merck & Co Inc Composiciones de canales calcicos humanos y procedimientos.
ES2151560T3 (es) * 1993-07-30 2001-01-01 Elan Pharm Inc Adn codificador de una subunidad alfa-1e de canales de calcio humanos.

Also Published As

Publication number Publication date
EP1042468B1 (de) 2006-10-18
WO1999028342A2 (en) 1999-06-10
EP1042468A2 (de) 2000-10-11
AU760309B2 (en) 2003-05-15
AU1802699A (en) 1999-06-16
JP2001525161A (ja) 2001-12-11
WO1999028342A3 (en) 1999-08-26
DE69836229D1 (de) 2006-11-30
DE69836229T2 (de) 2007-08-23
ES2274588T3 (es) 2007-05-16
CA2312195A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
ATE342973T1 (de) Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren
ATE139542T1 (de) Calciumkanal-zusammensetzungen und verfahren
GB9503692D0 (en) Human calcium channel compositions and methods of using them
GR3033961T3 (en) Human calcium channel compositions and methods.
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
WO2000005366A3 (en) Xiap ires and uses thereof
ES2193145T3 (es) Proteinas procoagulants quimericas.
DE69824445D1 (de) Zusammensetzungen zur wundheilung
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
GB9927292D0 (en) Security system
DK0778890T3 (da) DNA, som koder for en human calciumkanal-alpha-1E-underenhed
FR2757857B1 (fr) Diselenures et selenosulfures aromatiques, leur preparation et leurs utilisations, notamment therapeutiques
DE69905273D1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
BR9803694A (pt) ácidos 6- e 7-aminotetraidroisoquinolinacarboxìlico substituìdos.
PT941975E (pt) Cimento para injeccao contendo inibidores de corrosao
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties